Avior Wealth Management LLC Increases Stake in Teleflex Incorporated (NYSE:TFX)

Avior Wealth Management LLC raised its stake in shares of Teleflex Incorporated (NYSE:TFX) by 81.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 279 shares of the medical technology company’s stock after purchasing an additional 125 shares during the quarter. Avior Wealth Management LLC’s holdings in Teleflex were worth $50,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of TFX. Cromwell Holdings LLC lifted its stake in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 49 shares during the period. Ashton Thomas Securities LLC bought a new position in Teleflex during the 3rd quarter valued at about $40,000. True Wealth Design LLC lifted its stake in Teleflex by 16,600.0% during the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 166 shares during the period. GAMMA Investing LLC lifted its stake in Teleflex by 131.1% during the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after acquiring an additional 97 shares during the period. Finally, Quarry LP bought a new position in Teleflex during the 2nd quarter valued at about $48,000. Institutional investors own 95.62% of the company’s stock.

Analysts Set New Price Targets

TFX has been the topic of several research analyst reports. Truist Financial lowered their target price on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Royal Bank of Canada lowered their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Mizuho lowered their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Teleflex currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.50.

Teleflex Price Performance

NYSE TFX opened at $180.61 on Thursday. Teleflex Incorporated has a 12 month low of $171.69 and a 12 month high of $256.85. The stock has a market cap of $8.39 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 1.79 and a beta of 1.16. The company’s 50 day moving average is $182.40 and its two-hundred day moving average is $213.73. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $764.40 million for the quarter, compared to analysts’ expectations of $768.68 million. During the same quarter last year, the business earned $3.64 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year. As a group, research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current year.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.